Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
  • LinkedIn
  • Instagram
Research ArticleTools for Practice

Antihistamines for allergic rhinosinusitis

Betsy Thomas, Anthony Train and G. Michael Allan
Canadian Family Physician September 2022; 68 (9) 670; DOI: https://doi.org/10.46747/cfp.6809670
Betsy Thomas
Clinical Evidence Expert at the College of Family Physicians of Canada.
BScPharm
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony Train
Assistant Professor in the Department of Family Medicine at Queen’s University in Kingston, Ont.
MBChB MSc CCFP
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Michael Allan
Director of Programs and Practice Support at the College of Family Physicians of Canada.
MD CCFP FCFP
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

Clinical question

Do oral antihistamines (AHs) improve symptoms in adults with allergic rhinosinusitis?

Bottom line

Oral AHs reduce rhinosinusitis symptoms by 10% to 30% versus placebo over 2 to 12 weeks. Individual AHs appear to have comparable efficacy. More patients attain moderate improvement or better with intranasal corticosteroids (ICs) (about 80%) versus AHs (about 60%). There appear to be no meaningful differences between AHs and leukotriene receptor antagonists or when adding AHs to IC use.

Evidence

Results were statistically significant unless noted.

  • Antihistamines versus placebo over 2 to 12 weeks:

    • - Systematic review (7 RCTs, 1218 patients)1 found that for patient-rated nasal obstruction scores (scale 0 to 3), baseline=1.65; placebo improved symptoms 16% and AHs 48%.

    • - Systematic review (5 RCTs, 3329 patients)2 of bilastine (newer AH) found total symptom score effect size=0.28, similar to improving symptoms 10% to 16% over placebo.3

  • Antihistamines versus other AHs:

    • - Systematic reviews showed no statistical or clinical differences in total or nasal symptom scores.2,4

  • Antihistamines versus other agents:

    • - Two systematic reviews (5 to 16 RCTs, 990 to 2267 patients) compared ICs with AHs over 2 to 8 weeks.5,6 Total nasal symptom scores improved more with ICs (51% vs 31%). Proportion attaining moderate control or better7 was higher with intranasal steroids (78%) versus AHs (58%); number needed to treat=5.

    • - Systematic review (13 RCTs, 5066 patients)8 of AHs plus ICs versus ICs alone over 2 to 6 weeks found antihistamines did not add clinically meaningful benefit.

    • - Two systematic reviews (9 to 14 mixed-design studies, 4458 to 5781 patients) of AHs versus leukotriene receptor antagonist over 1 to 12 weeks found no clinically meaningful differences.9,10

Context

  • Adverse event data are reported infrequently and difficult to interpret.11 Some AHs may have less of a sedative effect: eg, bilastine (3%) versus cetirizine (7%).2

  • Estimated cost for 30-day supply: cetirizine 10 mg, desloratadine 5 mg, or fexofenadine 120 mg, $25; bilastine 20 mg, $45; mometasone 50 μg or beclomethasone 50 μg, $25; fluticasone 50 μg, $40.12

Implementation

Antihistamines have comparable efficacy, so choice should be based on cost and adverse event profile. Patients presenting in primary care typically have moderate to severe rhinosinusitis symptoms and more patients are likely to benefit from nasal steroids versus AHs.13 Improvement with nasal steroids may take several days and full effect can take up to 2 weeks.13

Notes

Tools for Practice articles in CFP are adapted from peer-reviewed articles at http://www.toolsforpractice.ca and summarize practice-changing medical evidence for primary care. Coordinated by Dr G. Michael Allan and Dr Adrienne J. Lindblad, articles are developed by the Patients, Experience, Evidence, Research (PEER) team and supported by the College of Family Physicians of Canada and its Alberta, Ontario, and Saskatchewan Chapters. Feedback is welcome at toolsforpractice{at}cfpc.ca.

Footnotes

  • Competing interests

    None declared

  • This article is eligible for Mainpro+ certified Self-Learning credits. To earn credits, go to https://www.cfp.ca and click on the Mainpro+ link.

  • La traduction en français de cet article se trouve à https://www.cfp.ca dans la table des matières du numéro de septembre 2022 à la page e268.

  • Copyright © 2022 the College of Family Physicians of Canada

References

  1. 1.↵
    1. Hore I,
    2. Georgalas C,
    3. Scadding G.
    Oral antihistamines for the symptom of nasal obstruction in persistent allergic rhinitis—a systematic review of randomized controlled trials. Clin Exp Allergy 2005;35(2):207–12. Erratum in: Clin Exp Allergy 2005;35(4):547.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Singh Randhawa A,
    2. Mohd Noor N,
    3. Md Daud MK,
    4. Abdullah B.
    Efficacy and safety of bilastine in the treatment of allergic rhinitis: a systematic review and meta-analysis. Front Pharmacol 2022;12:731201.
    OpenUrl
  3. 3.↵
    1. Bachert C,
    2. Kuna P,
    3. Sanquer F,
    4. Ivan P,
    5. Dimitrov V,
    6. Gorina MM, et al.
    Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy 2009;64(1):158–65.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Xiao J,
    2. Wu WX,
    3. Ye YY,
    4. Lin WJ,
    5. Wang L.
    A network meta-analysis of randomized controlled trials focusing on different allergic rhinitis medications. Am J Ther 2016;23(6):e1568–78.
    OpenUrl
  5. 5.↵
    1. Juel-Berg N,
    2. Darling P,
    3. Bolvig J,
    4. Foss-Skiftesvik MH,
    5. Halken S,
    6. Winther L, et al.
    Intranasal corticosteroids compared with oral antihistamines in allergic rhinitis: a systematic review and meta-analysis. Am J Rhinol Allergy 2017;31(1):19–28.
    OpenUrl
  6. 6.↵
    1. Weiner JM,
    2. Abramson MJ,
    3. Puy RM.
    Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ 1998;317(7173):1624–9.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Schoenwetter W,
    2. Lim J.
    Comparison of intranasal triamcinolone acetonide with oral loratadine for the treatment of patients with seasonal allergic rhinitis. Clin Ther 1995;17(3):479–92.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Du K,
    2. Qing H,
    3. Zheng M,
    4. Wang X,
    5. Zhang L.
    Intranasal antihistamine is superior to oral H1antihistamine as an add-on therapy to intranasal corticosteroid for treating allergic rhinitis. Ann Allergy Asthma Immunol 2020;125(5):589–96.e3. Epub 2020 Jul 7.
    OpenUrl
  9. 9.↵
    1. Xu Y,
    2. Zhang J,
    3. Wang J.
    The efficacy and safety of selective H1-antihistamine versus leukotriene receptor antagonist for seasonal allergic rhinitis: a meta-analysis. PLoS One 2014;9(11):e112815.
    OpenUrl
  10. 10.↵
    1. Feng Y,
    2. Meng YP,
    3. Dong YY,
    4. Qui CY,
    5. Cheng L.
    Management of allergic rhinitis with leukotriene receptor antagonists versus selective H1-antihistamines: a meta-analysis of current evidence. Allergy Asthma Clin Immunol 2021;17(1):62.
    OpenUrl
  11. 11.↵
    1. Bender BG,
    2. Berning S,
    3. Dudden R,
    4. Milgrom H,
    5. Tran ZV.
    Sedation and performance impairment of diphenhydramine and second-generation antihistamines: a meta-analysis. J Allergy Clin Immunol 2003;111(4):770–6.
    OpenUrlCrossRefPubMed
  12. 12.↵
    Allergy & sinus. Toronto, ON: Shoppers Drug Mart Corporation; 2022. Available from: https://shop.shoppersdrugmart.ca/. Accessed 2022 Jul 28.
  13. 13.↵
    1. Small P,
    2. Keith PK,
    3. Kim H.
    Allergic rhinitis. Allergy Asthma Clin Immunol 2018;14(Suppl 2):51.
    OpenUrl
PreviousNext
Back to top

In this issue

Canadian Family Physician: 68 (9)
Canadian Family Physician
Vol. 68, Issue 9
1 Sep 2022
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Antihistamines for allergic rhinosinusitis
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Antihistamines for allergic rhinosinusitis
Betsy Thomas, Anthony Train, G. Michael Allan
Canadian Family Physician Sep 2022, 68 (9) 670; DOI: 10.46747/cfp.6809670

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Antihistamines for allergic rhinosinusitis
Betsy Thomas, Anthony Train, G. Michael Allan
Canadian Family Physician Sep 2022, 68 (9) 670; DOI: 10.46747/cfp.6809670
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Clinical question
    • Bottom line
    • Evidence
    • Context
    • Implementation
    • Notes
    • Footnotes
    • References
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

  • Les antihistaminiques pour la rhinosinusite allergique
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Testosterone supplementation for men
  • Time to challenge penicillin allergy labels
  • Antibiotics for acute diverticulitis
Show more Tools for Practice

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • LinkedIn
  • Instagram
  • RSS Feeds

Copyright © 2025 by The College of Family Physicians of Canada

Powered by HighWire